Loading chat...
MA H3827
Bill
Status
2/27/2025
Primary Sponsor
Bruce Ayers
Click for details
AI Summary
-
Massachusetts General Court resolution urging U.S. Congress to update the Drug Addiction Treatment Act of 2000 by removing the 8-hour training requirement, exam, and special DEA "X license" needed to prescribe buprenorphine
-
Buprenorphine is a Schedule III drug used to treat opioid addiction, yet requires more stringent prescribing requirements than other Schedule III drugs and even some higher-risk Schedule II drugs
-
Resolution cites opioid crisis statistics: more than 2.1 million people with opioid use disorder, approximately 42,249 overdose deaths in 2016-2017, and over 130 daily U.S. deaths from opioid overdoses
-
Argues current prescribing requirements deter physicians from offering this medically-assisted treatment option for opioid addiction and withdrawal
-
If adopted, copies would be sent to the Vice President, Speaker of the House, and Massachusetts Congressional delegation
Legislative Description
Resolutions urging the Congress of the United States to update the Drug Addiction Treatment Act of 2000 and remove excessive training requirements mandated for obtaining a waiver to prescribe buprenorphine
Last Action
Resolutions reported favorably by committee and referred to the committee on House Steering, Policy and Scheduling
2/19/2026